Shares of Johnson & Johnson, which rose till 1.44% over the past week, on Tuesday closed with a decrease of 2.3%, despite on the publication of a better-than-expected Wall Street experts, a report for 3 fin. quarter.<\/p>\n
Investors are concerned about the potential consequences of ending the large-scale study of the J&J vaccine against COVID-19, designed to participate 60 thousand patients from different countries.<\/p>\n
The company has set up the special committee because one patient has been diagnosed with the “unexplained disease” and now experts are finding out whether this is a consequence of the vaccine. J&J announced the termination as a common practice, however, they do not predict how soon the final study will resume.<\/p>\n
For the 3rd quarter that ended September 30, Johnson & Johnson reported the following:<\/p>\n
Earnings per share rose to 4% (compared to last year) to $ 2.20, which is $ 0.22 more than analysts estimate at $ 1.98. Total quarterly profit rose to $ 5.87 billion from $ 5.67 billion in the same quarter last year.<\/p>\n
Total revenue grew from 2% to $ 21.1 billion, which is above the Wall Street average estimate of $ 20.2 billion.<\/p>\n
The main increase in the company’s revenue was due to the high sales of the medical equipment and the higher demand for some of the J&J`s drugs.<\/p>\n
The pharmaceutical division increased revenue by 5% to $ 11.4 billion. Consumer goods of the sales rose from 1.3% to $ 3.5 billion. The medical equipment division generated $ 6.1 billion, which is 1.7% more than in the same quarter last year.<\/p>\n
J&J raised its financial forecast for the year: earnings per share from the range of $ 7.75 – $ 7.95 to the range of $ 7.95 – $ 8.05, and the total sales forecast: from $ 79.9 billion. – $ 81.4 billion to $ 82 billion – $ 82.8 billion<\/p>\n
“Our world-class research team is working tirelessly to advance the third phase of testing of our COVID-19 vaccine and to adherence to the highest standards of the transparency, safety and efficiency,\u201d – said the CEO of J & J, Alex Gorsky, in the press release.<\/p>\n","protected":false},"featured_media":123940,"menu_order":0,"template":"","newscat":[9],"newstag":[29573,26317,24669,26898,24666,29572,29510,29511,29509,24258,24261],"issues":[],"class_list":["post-123939","news","type-news","status-publish","has-post-thumbnail","hentry","newscat-novosti","newstag-alex-gorsky","newstag-coronavirus","newstag-j-amp-j-2","newstag-j-amp-j","newstag-johnson-amp-johnson","newstag-vaccine-covid-19","newstag-aleks-gorsky","newstag-aleks-gorski","newstag-vakczyna-covid-19","newstag-koronavyrus","newstag-koronavirus"],"_links":{"self":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/news\/123939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/media\/123940"}],"wp:attachment":[{"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/media?parent=123939"}],"wp:term":[{"taxonomy":"newscat","embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/newscat?post=123939"},{"taxonomy":"newstag","embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/newstag?post=123939"},{"taxonomy":"issues","embeddable":true,"href":"https:\/\/ldaily.ua\/en\/wp-json\/wp\/v2\/issues?post=123939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}